Scinovex
articleTop 1% cited

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

European Journal of Endocrinology · 2006 · Vol. 154(6) · pp. 899–906

Abstract

Testosterone replacement therapy reduces insulin resistance and improves glycaemic control in hypogonadal men with type 2 diabetes. Improvements in glycaemic control, insulin resistance, cholesterol and visceral adiposity together represent an overall reduction in cardiovascular risk.

Hormonal and reproductive studiesPharmacology and Obesity TreatmentRegulation of Appetite and ObesityInternal medicineEndocrinologyMedicineType 2 diabetesInsulin resistanceTestosterone (patch)InsulinCrossover studyDiabetes mellitusPlacebo

MeSH terms

AgedBlood GlucoseDiabetes Mellitus, Type 2Double-Blind MethodHumansHypercholesterolemiaHypogonadismInsulin ResistanceMaleMiddle AgedTestosteroneCross-Over StudiesHormone Replacement TherapyAbdominal Fat
Citations
781
FWCI
27.67
field-weighted impact
References
45
Percentile
100%
vs. same field & year
Citations per year
Cited by
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes · Scinovex